SCHEMBL3605605

SCHEMBL3605605

Cn1nc(C(F)(F)F)c(C=O)c1Oc1cc(O)c(Cl)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 6/20 0.38
CYP2C19 P33261 5/20 0.38
CYP2D6 P10635 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CYP2C9 P11712 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
CYP1A1 P04798 1/20 0.34
DPP4 P27487 1/20 0.34
CYP1B1 Q16678 1/20 0.34
MAPK8 P45983 1/20 0.34
FPR2 P25090 1/20 0.34
PROKR1 Q8TCW9 1/20 0.34
PTGER4 P35408 1/20 0.33
CYP3A4 P08684 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
LMNA P02545 3/20 0.32
PRNP P04156 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3611386 0.88 CYP1A2 (0.34) CYP1A2CYP2C19CYP2D6CYP2C9L3MBTL1
SCHEMBL3605179 0.84 CYP1A2 (0.32) CYP1A2CYP2C19CYP2D6CYP2C9L3MBTL1
SCHEMBL3605182 0.84 CYP1A2 (0.32) CYP1A2CYP2C19CYP2D6CYP2C9L3MBTL1
SCHEMBL3608626 0.83 L3MBTL1 (0.35) CYP1A2CYP2C19SMN1; SMN2CYP2C9L3MBTL1
SCHEMBL3609801 0.83 SMN1; SMN2 (0.55) CYP1A2CYP2C19SMN1; SMN2CYP2C9L3MBTL1
SCHEMBL3605850 0.82 CYP1A2 (0.38) CYP1A2CYP2C19CYP2D6SMN1; SMN2CYP2C9
SCHEMBL3599883 0.81 SMN1; SMN2 (0.38) CYP1A2CYP2C19SMN1; SMN2CYP2C9PTGER4
SCHEMBL3616668 0.80 SMN1; SMN2 (0.38) CYP1A2CYP2C19SMN1; SMN2CYP2C9
SCHEMBL3600146 0.80 EPHA2 (0.38) CYP1A2CYP2C19SMN1; SMN2CYP2C9L3MBTL1
SCHEMBL3605185 0.80 EPHA2 (0.39) CYP1A2CYP2C19SMN1; SMN2CYP2C9L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R CYP1A2 137/4885CYP2C19 79/4885CYP2D6 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.